Editas Medicine (EDIT) Tops Q2 EPS by 21c, misses on revenue

Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.56), $0.21 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $2.89 million versus the consensus estimate of $4.17 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c